<SEC-DOCUMENT>0001193125-20-008085.txt : 20200115
<SEC-HEADER>0001193125-20-008085.hdr.sgml : 20200115
<ACCEPTANCE-DATETIME>20200115162102
ACCESSION NUMBER:		0001193125-20-008085
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200115
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200115
DATE AS OF CHANGE:		20200115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		20528483

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d874165d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT></B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): January&nbsp;15, 2020 </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Inovio Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-14888</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">33-0969592</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>660 W. Germantown Pike, Suite 110 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plymouth Meeting, PA 19462 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(267) <FONT STYLE="white-space:nowrap">440-4200</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock, $0.001 par value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>INO</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The Nasdaq Stock Market</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(d) Appointment of Jay Shepard as Director </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;15, 2020, the Board of Directors (the &#147;<B><I>Board</I></B>&#148;) of Inovio Pharmaceuticals, Inc. (the
&#147;<B><I>Company</I></B>&#148;) appointed Jay Shepard to serve as a director of the Company. Mr.&nbsp;Shepard&#146;s term will continue until the Company&#146;s 2020 Annual Meeting of Stockholders. There is no arrangement or understanding between
Mr.&nbsp;Shepard and any other person pursuant to which he was selected as a director of the Company, and there is no family relationship between Mr.&nbsp;Shepard and any of the Company&#146;s other directors or executive officers. The Company is
not aware of any transaction involving Mr.&nbsp;Shepard requiring disclosure under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional information regarding Mr.&nbsp;Shepard is set forth below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Jay Shepard</I>, age 61, is currently <FONT STYLE="white-space:nowrap">Non-executive</FONT> Chairman and formerly President and Chief
Executive Officer of Aravive, Inc. (formerly Versartis, Inc.) from May 2015 to January 2020 and has served as a member of its board of directors since 2013. From 2012 until May 2015, Mr.&nbsp;Shepard was an Executive Partner at Sofinnova Ventures, a
venture capital firm focused on the healthcare industry, which he joined as an Executive in Residence in 2008. From 2010 to 2012, Mr.&nbsp;Shepard served as President and Chief Executive Officer and was a member of the board of directors of NextWave
Pharmaceuticals, Inc., a specialty pharmaceutical company developing and commercializing unique pediatric products utilizing proprietary drug delivery technology that was acquired by Pfizer, Inc. From 2005 to 2007, Mr.&nbsp;Shepard served as
President and Chief Executive Officer and a member of the board of directors of Ilypsa, Inc., a biopharmaceutical company pioneering novel <FONT STYLE="white-space:nowrap">non-absorbed</FONT> polymeric drugs for renal and metabolic disorders that
was acquired by Amgen Inc. Mr.&nbsp;Shepard currently serves on the board of directors of Esperion Therapeutics, Inc., a publicly traded pharmaceutical company, and of the Christopher&nbsp;&amp; Dana Reeve Foundation. Within the past five years,
Mr.&nbsp;Shepard also served on the boards of directors of the public companies Marinus Pharmaceuticals, Inc. and Durect Corporation. Mr.&nbsp;Shepard holds a B.S. in Business Administration from the University of Arizona. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Shepard will be compensated in accordance with the Company&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> director
compensation policy. He will receive an annual cash retainer of $45,000 for serving on the Board. In addition, Mr.&nbsp;Shepard received initial equity awards under and pursuant to the Company&#146;s 2016 Omnibus Incentive Plan upon his appointment
as of January&nbsp;15, 2020 the date of grant. As a newly elected director, Mr.&nbsp;Shepard was awarded 12,821<B> </B>restricted stock units and a stock option to purchase 20,000 of the Company&#146;s common stock at an exercise price of $3.35, the
closing price of the Company&#146;s common stock on the date of grant. The restricted stock units will vest over a period of three years, with <FONT STYLE="white-space:nowrap">one-third</FONT> of the shares vesting on each of the first, second and
third anniversaries of the grant date, subject to Mr.&nbsp;Shepard&#146;s continued service as a director of the Company as of each vesting date. With respect to the shares of common stock underlying the stock option grant, <FONT
STYLE="white-space:nowrap">one-quarter</FONT> of the shares vested as of the grant date, with the remainder vesting in three equal annual installments on the first, second and third anniversaries of the grant date, subject to Mr.&nbsp;Shepard&#146;s
continued service as a director of the Company as of each vesting date. Mr.&nbsp;Shepard will be eligible to receive additional annual equity awards on each date of the Company&#146;s annual meeting of stockholders in accordance with the <FONT
STYLE="white-space:nowrap">non-employee</FONT> director compensation policy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b) Retirement of Morton Collins as Director </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;14, 2020, Morton Collins notified the Company of his retirement from the Board, effective immediately. Dr.&nbsp;Collins&#146;
retirement as a director of the Company was not the result of any dispute or disagreement with the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulation FD Disclosure. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;15, 2020, the Company issued a press release announcing the appointment of Mr.&nbsp;Shepard to the Board and the retirement of
Mr.&nbsp;Collins from the Board. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report. The information contained in the press release furnished as Exhibit 99.1 shall not be deemed &#147;filed&#148; for purposes
of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;<B><I>Exchange Act</I></B>&#148;), and is not incorporated by reference into any of the Company&#146;s filings under the Securities Act of 1933, as amended, or the
Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit<BR>No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d874165dex991.htm">Press Release, dated January&nbsp;15, 2020. </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INOVIO PHARMACEUTICALS, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date: January&nbsp;15, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Peter Kies</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Kies</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d874165dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g874165snap046.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>CONTACTS: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Investors: Ben Matone, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">484-362-0076,</FONT></FONT>
<U>ben.matone@inovio.com</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Media: Jeff Richardson,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">267-440-4211,</FONT></FONT> <U>jrichardson@inovio.com</U> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inovio
Welcomes Biotech Leader </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>To its Board of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inovio also announces retirement of long-serving board member </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">PLYMOUTH MEETING, PA &#150; January&nbsp;15, 2020 &#150; Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the appointment of Jay
Shepard to its Board of Directors. Mr.<U></U>&nbsp;Shepard brings broad healthcare and financial experience to the board given his tenure as CEO of several biotech companies, his multiple corporate board appointments and his expertise as a
healthcare venture capitalist. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;J. Joseph Kim, Inovio&#146;s President<U></U>&nbsp;&amp; CEO said, &#147;We are fortunate to have
Jay Shepard join Inovio&#146;s Board of Directors. Jay&#146;s expertise in health care, corporate financing and M&amp;A in the industry will be an asset to our company as we execute on our strategic deliverables in the next year and the next
decade.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Inovio also announced the retirement of Mort Collins from its Board. Dr.&nbsp;Collins had been a founding Board member of
Inovio&#146;s predecessor, VGX Pharmaceuticals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Regarding Mort Collins, Dr.&nbsp;Kim said, &#147;For almost two decades Mort has been a
guiding hand for Inovio helping us grow and make the right choices in science and business. For me, Mort has been more than a corporate board member. He has been a mentor to me and a strong voice I&#146;ve relied on to manage innovation as we
develop and commercialize our DNA medicines.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>About Jay Shepard </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Mr.&nbsp;Shepard is currently Non-executive Chairman and formerly President and Chief Executive Officer of Aravive, a clinical-stage
biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. Previously, Mr.<U></U>&nbsp;Shepard was an Executive Partner at Sofinnova Ventures, a healthcare venture
capital firm. Before that he also served as President and Chief Executive Officer and was a member of the board of directors of NextWave Pharmaceuticals, Inc., a specialty pharmaceutical company developing and commercializing unique pediatric
products utilizing proprietary drug delivery technology that was acquired by Pfizer, Inc. Mr.<U></U>&nbsp;Shepard has also served as President and Chief Executive Officer and a member of the board of directors of Ilypsa, Inc., a
</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
biopharmaceutical company pioneering novel <FONT STYLE="white-space:nowrap">non-absorbed</FONT> polymeric drugs for renal and metabolic disorders that was acquired by Amgen. Mr.&nbsp;Shepard has
held board appointments for numerous public and private companies, including Ilypsa, Inc., Relypsa, Inc., Intermune, Inc., Bullet Biotechnology, Inc., Marinus Pharmaceuticals, Inc., and Durect Corporation. Currently, Mr.<U></U>&nbsp;Shepard serves
on the board of directors of Esperion Therapeutics, Inc., a pharmaceutical company, and of the Christopher<U></U>&nbsp;&amp; Dana Reeve Foundation. Mr.<U></U>&nbsp;Shepard holds a B.S. in Business Administration from the University of Arizona. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>About Inovio Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure and/or protect people
from diseases associated with HPV, cancer, and infectious diseases. Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to safely
produce a robust immune response to destroy and clear high-risk HPV 16 and 18, which are responsible for 70% of cervical cancer, 90% of anal cancer and 69% of vulvar cancer. In addition to HPV, Inovio&#146;s optimized plasmid design and delivery
technology has been demonstrated to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. Inovio&#146;s most advanced clinical program,
<FONT STYLE="white-space:nowrap">VGX-3100,</FONT> is in Phase 3 development for the treatment of <FONT STYLE="white-space:nowrap">HPV-related</FONT> cervical <FONT STYLE="white-space:nowrap">pre-cancer.</FONT> Also in development are Phase 2
immuno-oncology programs targeting <FONT STYLE="white-space:nowrap">HPV-related</FONT> cancers and GBM, as well as externally funded platform development programs in Zika, MERS, Lassa, and HIV. Partners and collaborators include ApolloBio
Corporation, AstraZeneca, The Bill&nbsp;&amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency, GeneOne Life Science, HIV Vaccines Trial Network, Medical CBRN Defense
Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Regeneron, Roche/Genentech, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar
Institute. For more information, visit <U>www.inovio.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>This press release contains certain forward-looking statements relating to our business, including our plans to develop DNA medicines, our
expectations regarding our research and development programs, as well as commercialization activities, including the planned initiation and conduct of clinical trials, the availability and timing of data from those trials and our commercialization
strategy and tactics. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, clinical trials,
product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or
develop viable DNA vaccines, our ability to support our pipeline of SynCon<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> active immunotherapy and vaccine products, the ability of our collaborators to attain development and commercial
milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the
conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving
patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others
or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential
corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2018, our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2019, and other filings we make from time to time with the Securities and Exchange Commission. There can be no
assurance that any product candidate in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the
forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.
</I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g874165snap046.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g874165snap046.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( 'H"@0,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /?Z "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M>-AE64Y!'J#0 Z@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M^(Y+*)_]#L28U /#/_$WY\?A3 U_AGX&@U)!K>JQ"2V#8MX6'#D=6/J >,4
M>QJH10J@!0, #M2 6@#G/%O@^Q\4V#+(BQ7J+^YN .0?0^HH ^?'6\T35BI+
M07EI+C(ZJRFF(^C_  QK:>(?#UIJ*@!Y%Q(H_A<<,/SI#->@ H * "@ H *
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MS9DN;J3.%'4D\ #]!3$?1'@[0O\ A'?#%I8N!Y^/,FQ_?/)_+@?A2&;U !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M][=R' SEF/L!_04"/6_A_P##IM)DCU?6$!O!S#!U$7N?]K^7UZ(9Z30 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * *&IZ1;:LL:W,MX@C)(^S7LUN3GU\MES^- &=_PANE_\_6L_P#@[O/_
M ([0 ?\ "&Z7_P _6L_^#N\_^.T '_"&Z7_S]:S_ .#N\_\ CM !_P (;I?_
M #]:S_X.[S_X[0 ?\(;I?_/UK/\ X.[S_P".T '_  ANE_\ /UK/_@[O/_CM
M !_PANE_\_6L_P#@[O/_ ([0 ?\ "&Z7_P _6L_^#N\_^.T '_"&Z7_S]:S_
M .#N\_\ CM !_P (;I?_ #]:S_X.[S_X[0 ?\(;I?_/UK/\ X.[S_P".T '_
M  ANE_\ /UK/_@[O/_CM !_PANE_\_6L_P#@[O/_ ([0 ?\ "&Z7_P _6L_^
M#N\_^.T '_"&Z7_S]:S_ .#N\_\ CM !_P (;I?_ #]:S_X.[S_X[0 ?\(;I
M?_/UK/\ X.[S_P".T '_  ANE_\ /UK/_@[O/_CM !_PANE_\_6L_P#@[O/_
M ([0 ?\ "&Z7_P _6L_^#N\_^.T '_"&Z7_S]:S_ .#N\_\ CM !_P (;I?_
M #]:S_X.[S_X[0 ?\(;I?_/UK/\ X.[S_P".T '_  ANE_\ /UK/_@[O/_CM
M !_PANE_\_6L_P#@[O/_ ([0 ?\ "&Z7_P _6L_^#N\_^.T '_"&Z7_S]:S_
M .#N\_\ CM !_P (;I?_ #]:S_X.[S_X[0 ?\(;I?_/UK/\ X.[S_P".T '_
M  ANE_\ /UK/_@[O/_CM !_PANE_\_6L_P#@[O/_ ([0 ?\ "&Z7_P _6L_^
M#N\_^.T '_"&Z7_S]:S_ .#N\_\ CM !_P (;I?_ #]:S_X.[S_X[0 ?\(;I
M?_/UK/\ X.[S_P".T '_  ANE_\ /UK/_@[O/_CM !_PANE_\_6L_P#@[O/_
M ([0 ?\ "&Z7_P _6L_^#N\_^.T '_"&Z7_S]:S_ .#N\_\ CM !_P (;I?_
M #]:S_X.[S_X[0 ?\(;I?_/UK/\ X.[S_P".T '_  ANE_\ /UK/_@[O/_CM
M !_PANE_\_6L_P#@[O/_ ([0 ?\ "&Z7_P _6L_^#N\_^.T '_"&Z7_S]:S_
M .#N\_\ CM !_P (;I?_ #]:S_X.[S_X[0 ?\(;I?_/UK/\ X.[S_P".T '_
M  ANE_\ /UK/_@[O/_CM !_PANE_\_6L_P#@[O/_ ([0 ?\ "&Z7_P _6L_^
M#N\_^.T '_"&Z7_S]:S_ .#N\_\ CM !_P (;I?_ #]:S_X.[S_X[0 ?\(;I
M?_/UK/\ X.[S_P".T '_  ANE_\ /UK/_@[O/_CM !_PANE_\_6L_P#@[O/_
M ([0 ?\ "&Z7_P _6L_^#N\_^.T '_"&Z7_S]:S_ .#N\_\ CM !_P (;I?_
M #]:S_X.[S_X[0 ?\(;I?_/UK/\ X.[S_P".T '_  ANE_\ /UK/_@[O/_CM
M !_PANE_\_6L_P#@[O/_ ([0 ?\ "&Z7_P _6L_^#N\_^.T '_"&Z7_S]:S_
M .#N\_\ CM !_P (;I?_ #]:S_X.[S_X[0 ?\(;I?_/UK/\ X.[S_P".T '_
M  ANE_\ /UK/_@[O/_CM !_PANE_\_6L_P#@[O/_ ([0 ?\ "&Z7_P _6L_^
M#N\_^.T '_"&Z7_S]:S_ .#N\_\ CM !_P (;I?_ #]:S_X.[S_X[0 ?\(;I
M?_/UK/\ X.[S_P".T '_  ANE_\ /UK/_@[O/_CM !_PANE_\_6L_P#@[O/_
M ([0 ?\ "&Z7_P _6L_^#N\_^.T '_"&Z7_S]:S_ .#N\_\ CM !_P (;I?_
M #]:S_X.[S_X[0 ?\(;I?_/UK/\ X.[S_P".T ;%E9Q6%JMO"TS(O0S3O,WX
MLY)/XF@"Q0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
1 % !0 4 % !0 4 % !0!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
